Enhanced Sensitivity to Glucocorticoids in Cytarabine-resistant AML

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2016 Nov 12

PMID 27833094

Citations 22

Authors

D Malani

A Murumagi

B Yadav

M Kontro

S Eldfors

A Kumar

R Karjalainen

M M Majumder

P Ojamies

T Pemovska

K Wennerberg

C Heckman

K Porkka

M Wolf

T Aittokallio

O Kallioniemi

Affiliations

Soon will be listed here.

Abstract

We sought to identify drugs that could counteract cytarabine resistance in acute myeloid leukemia (AML) by generating eight resistant variants from MOLM-13 and SHI-1 AML cell lines by long-term drug treatment. These cells were compared with 66 ex vivo chemorefractory samples from cytarabine-treated AML patients. The models and patient cells were subjected to genomic and transcriptomic profiling and high-throughput testing with 250 emerging and clinical oncology compounds. Genomic profiling uncovered deletion of the deoxycytidine kinase (DCK) gene in both MOLM-13- and SHI-1-derived cytarabine-resistant variants and in an AML patient sample. Cytarabine-resistant SHI-1 variants and a subset of chemorefractory AML patient samples showed increased sensitivity to glucocorticoids that are often used in treatment of lymphoid leukemia but not AML. Paired samples taken from AML patients before treatment and at relapse also showed acquisition of glucocorticoid sensitivity. Enhanced glucocorticoid sensitivity was only seen in AML patient samples that were negative for the FLT3 mutation (P=0.0006). Our study shows that development of cytarabine resistance is associated with increased sensitivity to glucocorticoids in a subset of AML, suggesting a new therapeutic strategy that should be explored in a clinical trial of chemorefractory AML patients carrying wild-type FLT3.

Citing Articles

CSE1L Silencing Enhances Cytarabine-mediated Cytotoxicity in Acute Myeloid Leukemia.

Liu X, Yang L, Guan K, Chen Z, Yang H Indian J Hematol Blood Transfus. 2024; 40(4):629-637.

PMID: 39469152 PMC: 11512944. DOI: 10.1007/s12288-024-01773-3.

Theoretical aspects of interaction of the anticancer drug cytarabine with human serum albumin.

Amirinasab M, Dehestani M Struct Chem. 2023; :1-9.

PMID: 37363044 PMC: 10052281. DOI: 10.1007/s11224-023-02164-6.

Dexamethasone enhances venetoclax-induced apoptosis in acute myeloid leukemia cells.

Wang H, Zhou J, Ma X, Jiao C, Chen E, Wu Z Med Oncol. 2023; 40(7):193.

PMID: 37261571 DOI: 10.1007/s12032-023-02056-z.

Drug-adapted cancer cell lines as preclinical models of acquired resistance.

Michaelis M, Wass M, Cinatl J Cancer Drug Resist. 2022; 2(3):447-456.

PMID: 35582596 PMC: 8992517. DOI: 10.20517/cdr.2019.005.

The glucocorticoid receptor associates with the cohesin loader NIPBL to promote long-range gene regulation.

Rinaldi L, Fettweis G, Kim S, Garcia D, Fujiwara S, Johnson T Sci Adv. 2022; 8(13):eabj8360.

PMID: 35353576 PMC: 8967222. DOI: 10.1126/sciadv.abj8360.

References

Rowe J, Kim H, Cassileth P, Lazarus H, Litzow M, Wiernik P . Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. Cancer. 2010; 116(21):5012-21. PMC: 3566633. DOI: 10.1002/cncr.25263. View

Cros E, Jordheim L, Dumontet C, Galmarini C . Problems related to resistance to cytarabine in acute myeloid leukemia. Leuk Lymphoma. 2004; 45(6):1123-32. DOI: 10.1080/1042819032000159861. View

Kaspers G, Veerman A, Popp-Snijders C, Lomecky M, van Zantwijk C, Swinkels L . Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1996; 27(2):114-21. DOI: 10.1002/(SICI)1096-911X(199608)27:2<114::AID-MPO8>3.0.CO;2-I. View

Ogbomo H, Michaelis M, Klassert D, Doerr H, Cinatl Jr J . Resistance to cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cells. Neoplasia. 2008; 10(12):1402-10. PMC: 2586691. DOI: 10.1593/neo.08972. View

MORRISON F, Kopecky K, Head D, Athens J, Balcerzak S, Gumbart C . Late intensification with POMP chemotherapy prolongs survival in acute myelogenous leukemia--results of a Southwest Oncology Group study of rubidazone versus adriamycin for remission induction, prophylactic intrathecal therapy, late intensification,.... Leukemia. 1992; 6(7):708-14. View

Xie C, Edwards H, Caldwell J, Wang G, Taub J, Ge Y . Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage. Mol Oncol. 2014; 9(2):409-21. PMC: 4305021. DOI: 10.1016/j.molonc.2014.09.008. View

Rowe J . Optimal induction and post-remission therapy for AML in first remission. Hematology Am Soc Hematol Educ Program. 2009; :396-405. DOI: 10.1182/asheducation-2009.1.396. View

Tissing W, Meijerink J, den Boer M, Pieters R . Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia. 2003; 17(1):17-25. DOI: 10.1038/sj.leu.2402733. View

Nishi R, Yamauchi T, Negoro E, Takemura H, Ueda T . Combination of guanine arabinoside and Bcl-2 inhibitor YC137 overcomes the cytarabine resistance in HL-60 leukemia cell line. Cancer Sci. 2013; 104(4):502-7. PMC: 7657161. DOI: 10.1111/cas.12103. View

10.

Faderl S, Gandhi V, OBrien S, Bonate P, Cortes J, Estey E . Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2004; 105(3):940-7. DOI: 10.1182/blood-2004-05-1933. View

11.

Tang J, Szwajda A, Shakyawar S, Xu T, Hintsanen P, Wennerberg K . Making sense of large-scale kinase inhibitor bioactivity data sets: a comparative and integrative analysis. J Chem Inf Model. 2014; 54(3):735-43. DOI: 10.1021/ci400709d. View

12.

Rathe S, Largaespada D . Deoxycytidine kinase is downregulated in Ara-C-resistant acute myeloid leukemia murine cell lines. Leukemia. 2010; 24(8):1513-5. DOI: 10.1038/leu.2010.88. View

13.

Yadav B, Pemovska T, Szwajda A, Kulesskiy E, Kontro M, Karjalainen R . Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci Rep. 2014; 4:5193. PMC: 4046135. DOI: 10.1038/srep05193. View

14.

Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A . Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 2013; 3(12):1416-29. DOI: 10.1158/2159-8290.CD-13-0350. View

15.

Mariotta M, Perewusnyk G, Koechli O, Little J, Knebel Doeberitz M, Mirimanoff R . Dexamethasone-induced enhancement of resistance to ionizing radiation and chemotherapeutic agents in human tumor cells. Strahlenther Onkol. 1999; 175(8):392-6. DOI: 10.1007/s000660050027. View

16.

Nowak D, Liem N, Mossner M, Klaumunzer M, Papa R, Nowak V . Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance. Exp Hematol. 2014; 43(1):32-43.e1-35. PMC: 5894481. DOI: 10.1016/j.exphem.2014.09.007. View

17.

Negoro E, Yamauchi T, Urasaki Y, Nishi R, Hori H, Ueda T . Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses. Int J Oncol. 2011; 38(4):911-9. DOI: 10.3892/ijo.2011.933. View

18.

Kobune M, Takimoto R, Murase K, Iyama S, Sato T, Kikuchi S . Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells. Cancer Sci. 2009; 100(5):948-55. PMC: 11158794. DOI: 10.1111/j.1349-7006.2009.01111.x. View

19.

Klanova M, Lorkova L, Vit O, Maswabi B, Molinsky J, Pospisilova J . Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents. Mol Cancer. 2014; 13:159. PMC: 4094598. DOI: 10.1186/1476-4598-13-159. View

20.

Keith F, Bradbury D, Zhu Y, Russell N . Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia. 1995; 9(1):131-8. View